



## **CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents**

February 15, 2017

BASEL, Switzerland and CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that management will host a conference call and live audio webcast on Thursday, February 16, 2017 at 11:00 a.m. ET to provide an update on the CRISPR/Cas9 U.S. Patent Interference Proceedings as well as an update on the corresponding U.K. patents.

To access the conference call, please dial +1 (844) 358-8762 (domestic) or +1 (703) 736-7374 (international) and reference the conference ID number 74645402. To join the live webcast, please visit the "Investors & Media" section of the CRISPR Therapeutics website at [www.crisprtx.com](http://www.crisprtx.com).

A webcast replay will be available on the CRISPR Therapeutics website beginning approximately two hours after the event and will be archived for 30 days.

### **CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the Company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit [www.crisprtx.com](http://www.crisprtx.com).

### **MEDIA CONTACTS:**

Jennifer Paganelli  
W2O Group for CRISPR  
347-658-8290 [jpaganelli@w2ogroup.com](mailto:jpaganelli@w2ogroup.com)

### **INVESTOR CONTACT:**

Chris Brinzey  
Westwicke Partners for CRISPR  
339-970-2843 [chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



CRISPR Therapeutics AG